

Thus, the phrase "claims 1-15" in each of claims 16-22 has been changed to --claims 1-14 or 15--. In accordance with 37 CFR §1.121(b), a marked-up version of these claims is appended hereto, with additions noted by underlining and deletions noted by brackets. Claim 31 was cancelled and separated into three new claims, 32-34. No new matter has been introduced.

Applicants respectfully submit that the amendments provided herewith overcome the objections and, accordingly, ask that the Examiner reconsider and withdraw these objections.

Submission of Information Disclosure Statement

In accordance with 37 CFR 1.97-98, an information disclosure statement on an attached Form PTO-SB/08a is enclosed. The items identified may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be construed as an admission that any such patent, publication or other information referred to therein is material, or even qualifies as "prior art" under the patent laws.




Patent  
030639.0043.UTL

The Examiner is hereby authorized to debit deposit account number 50-1273 for the appropriate amount due under this response. Applicants calculate this to be \$18.00 for the three new and one canceled dependent claims.

Respectfully submitted,

Brobeck, Phleger & Harrison LLP

Dated: 8-1-01

By:   
Bradford J. Duft  
Reg. No 32,219

BROBECK, PHLEGER & HARRISON LLP  
12390 El Camino Real  
San Diego, CA 92130  
Phone (858) 720-2500  
Fax (858) 720-2555

Marked-UP Version of Claims

16. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin is exendin-3.
17. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin is exendin-4.
18. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide, and <sup>14</sup>Leu, <sup>22</sup>Ala, <sup>25</sup>Phe exendin-4 (1-28) amide.
19. (Amended) The method according to any of claims [1-15] 1-14 or 15, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting [essential] of an amylin agonist, a leptin, and a CCK.
20. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula I.
21. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula II.
22. (Amended) The method according to any of claims [1-15] 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula III.